Switch theme
Sign up to access all valuation multiples
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
2011
130
LTM Revenue $242M
LTM EBITDA n/a
$783M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Aurinia Pharmaceuticals has a last 12-month revenue of $242M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Aurinia Pharmaceuticals achieved revenue of $235M and an EBITDA of $31.7M.
Aurinia Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Aurinia Pharmaceuticals valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $176M | $235M | XXX | XXX | XXX |
| Gross Profit | $128M | $161M | XXX | XXX | XXX |
| Gross Margin | 73% | 69% | XXX | XXX | XXX |
| EBITDA | -$63.0M | $31.7M | XXX | XXX | XXX |
| EBITDA Margin | -36% | 13% | XXX | XXX | XXX |
| Net Profit | -$108M | -$78.0M | XXX | XXX | XXX |
| Net Margin | -62% | -33% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Aurinia Pharmaceuticals's stock price is $8.
Aurinia Pharmaceuticals has current market cap of $1.1B, and EV of $783M.
See Aurinia Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $783M | $1.1B | XXX | XXX | XXX | XXX | $0.16 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Aurinia Pharmaceuticals has market cap of $1.1B and EV of $783M.
Aurinia Pharmaceuticals's trades at 3.2x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Aurinia Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Aurinia Pharmaceuticals and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $783M | XXX | XXX | XXX |
| EV/Revenue | 3.3x | XXX | XXX | XXX |
| EV/EBITDA | 24.7x | XXX | XXX | XXX |
| P/E | 184.6x | XXX | XXX | XXX |
| P/E/Growth | 0.6x | XXX | XXX | XXX |
| EV/FCF | 17.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAurinia Pharmaceuticals's NTM/LTM revenue growth is 14%
Aurinia Pharmaceuticals's revenue per employee for the last fiscal year averaged $1.8M, while opex per employee averaged $1.4M for the same period.
Over next 12 months, Aurinia Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Aurinia Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Aurinia Pharmaceuticals and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 34% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 13% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -150% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 28% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $1.8M | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.4M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 6% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 67% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 9% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 80% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Aurinia Pharmaceuticals acquired XXX companies to date.
Last acquisition by Aurinia Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Aurinia Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Aurinia Pharmaceuticals founded? | Aurinia Pharmaceuticals was founded in 2011. |
| Where is Aurinia Pharmaceuticals headquartered? | Aurinia Pharmaceuticals is headquartered in United States of America. |
| How many employees does Aurinia Pharmaceuticals have? | As of today, Aurinia Pharmaceuticals has 130 employees. |
| Who is the CEO of Aurinia Pharmaceuticals? | Aurinia Pharmaceuticals's CEO is Mr. Peter S. Greenleaf. |
| Is Aurinia Pharmaceuticals publicy listed? | Yes, Aurinia Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of Aurinia Pharmaceuticals? | Aurinia Pharmaceuticals trades under AUPH ticker. |
| When did Aurinia Pharmaceuticals go public? | Aurinia Pharmaceuticals went public in 2009. |
| Who are competitors of Aurinia Pharmaceuticals? | Similar companies to Aurinia Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Aurinia Pharmaceuticals? | Aurinia Pharmaceuticals's current market cap is $1.1B |
| What is the current revenue of Aurinia Pharmaceuticals? | Aurinia Pharmaceuticals's last 12-month revenue is $242M. |
| What is the current EV/Revenue multiple of Aurinia Pharmaceuticals? | Current revenue multiple of Aurinia Pharmaceuticals is 3.2x. |
| What is the current revenue growth of Aurinia Pharmaceuticals? | Aurinia Pharmaceuticals revenue growth between 2023 and 2024 was 34%. |
| Is Aurinia Pharmaceuticals profitable? | Yes, Aurinia Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
